Stock Ratings / Health Care / CPIX / financials

GOSS (33) SPRO (43) FBIO (39) RNXT (31) ⌘ Pro Terminal →

Cumberland Pharmaceuticals Inc. (CPIX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.69 +7.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.75

Cumberland Pharmaceuticals Inc. (CPIX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $65.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CPIX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.69 (+7.82% 1D, market cap $65.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, CPIX ranks #590 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CPIX compare to GOSS and SPRO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CPIX?

▼

Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.75 (+1.22%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 10.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPIX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY CPIX SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (29% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$7.03+2.1% Next Q

Q2 (-2Q)

Grade D$7.18+18.2% Next Q

Q3 (-1Q)

Grade D$8.49-44.8% Next Q

Current

Grade D-$4.69-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CPIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CPIX currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.12) and Max Pain ($4.92) forces dealer call-delta covering toward $9.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CPIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CPIX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$4.8M (10.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $39.6M

FY24

Rev $37.9M

FY25

Rev $44.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$44.5M	85%	-6.3%	-$2.8M	$4.8M	-16.4%
FY 2024	$37.9M	82.6%	-17%	-$6.5M	-$678.6K	-45%
FY 2023	$39.6M	85%	-24.2%	-$6.3M	$6.1M	-16.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPIX)

✓Walkthrough of CPIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CPIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.93%▼ DESCENDING CHANNEL

2026-10-30O $4.35H $4.76L $4.35C $4.69VOL 129.0K

RES: $8.70SUP: $4.16SMA50: $7.12SMA200: $5.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CPIX Butterfly Map → + Track CPIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CPIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CPIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CPIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPIX)

Health Care Rank #590 of 1016 ⚔️ GOSS vs CPIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CPIX vs. GOSS, SPRO, FBIO, RNXT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cumberland Pharmaceuticals Inc. (CPIX) ranks #590 by composite RQD confidence (38/100, grade D-) and #718 by equity capitalization ($65.2M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. SPRO currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CPIX at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CPIX ACTIVE Cumberland Pharmaceuticals Inc.	D-	38/100	—	85.0%	-16.4%	+7.82%	$65.2M	Benchmark Subject
GOSS Gossamer Bio Inc.	E	33/100	—	—	-35.0%	-2.90%	$65.4M	/goss-vs-cpix →
SPRO Spero Therapeutics Inc.	D-	43/100	7.5x	—	26.6%	-4.50%	$64.6M	/spro-vs-cpix →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-cpix →
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-cpix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001087294

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cumberland Pharmaceuticals Inc. (CPIX) reported GAAP revenue of $44.5M (+17.6% vs. FY2024 revenue of $37.9M , and +12.6% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of $4.9M, and free cash flow of $4.8M (+812.4% YoY). On the balance sheet, CPIX closed FY2025 with $76.8M in total assets against $0 in total debt (Altman Z-Score: 0.72, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.5M	-$2.8M	$4.9M	$4.8M	$76.8M	—
FY2024 (FY)	2024-12-31	$37.9M	-$6.5M	-$612.2K	-$678.6K	$75.6M	—
FY2023 (FY)	2023-12-31	$39.6M	-$6.3M	$6.1M	$6.1M	—	—

3. CPIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CPIX compare to GOSS and SPRO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CPIX?

Where is CPIX trading relative to its 50-day, 200-day, and 52-week technical levels?

CPIX last traded at $4.69 (+7.82% on volume of 128,962 shares), positioning the stock -34.13% below its 50-day simple moving average ($7.12) and -15.04% below its 200-day simple moving average ($5.52). Across its 52-week range of $1.85 to $9.28, CPIX sits at the 38.2% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.10 to $5.28).

CPIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Cumberland Pharmaceuticals Inc. (CPIX)?

In FY 2025 (10-K), CPIX converted $44.5M of revenue into a 85% gross margin, 0% operating margin, and $4.8M in free cash flow (10.9% FCF margin).

Direct Sub-Reports: CPIX RQD Cockpit CPIX 12M Forecast CPIX Earnings & Move CPIX Dividends & DRIP CPIX Insiders & 13F CPIX Whale Options CPIX Profit Sankey CPIX News & Why